Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein

Molecular Pharmacology

Volumn 68, Issue 6, 2005, Pages 1543-1550

  Akiyama, Hideo ^a   Mohamedali, Khalid A ^b   Lima E Silva, Raquel ^a   Kachi, Shu ^a   Shen, JiKui ^a   Hatara, Christina ^a   Umeda, Naoyasu ^a   Hackett, Sean F ^a   Aslam, Sadia ^a   Krause, Melissa ^a   Lai, Hong ^a   Rosenblum, Michael G ^b   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELONIN; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC CIRCULATION; UPREGULATION;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; MICE; PLANT PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27844575205     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.015628     Document Type: Article

References (41)

1. Adamis AP, Miller JW, Bernal M-T, D'Amico DJ, Folkman J, Yeo T-K, and Yeo K-T (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450.
2. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, and Miller JW (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization. Arch Ophthalmol 114:66-71.
3. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487.
4. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, and Smith LEH (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457-10461.
5. Arora N, Masood R, Zheng T, Cai J, Smith DL, and Gill PS (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59:183-188.
6. Baluk P, Morikawa S, Haskell A, Mancuso M, and McDonald DM (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163:1801-1815.
7. Brooks P, Clark R, and Cheresh D (1994) Requirement of vascular integrin alpha-v beta-3 for angiogenesis. Science (Wash DC) 264:569-571.
8. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, and Kinzler KW (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61:6649-6655.
9. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, and Munn LL (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97:14608-14613.
10. Denekamp J (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23:217-225.
11. Denekamp J (1999) The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Investig 29:733-736.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, and Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816.
13. Hazhizume H, Baluk P, McLean JW, Thurston G, Roberge S, Jain RK, and McDonald DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380.
14. Klein R, Klein BEK, Moss SE, Davis MD, and DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526.
15. Kwak N, Okamoto N, Wood JM, and Campochiaro PA (2000) VEGF is an important stimulator in a model of choroidal neovascularization. Investig Ophthalmol Vis Sci 41:3158-3164.
16. Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, and Edgington TS (2002) Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62:5470-5475.
17. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, and Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629-3634.
18. 121 and the serine protease granzyme B: directed events in vascular endothelial cells. Mol Cancer Ther 2:949-959.
19. Luna J, Tobe T, Mousa SA, Reilly TM, and Campochiaro PA (1996) Antagonists of integrin alpha-v beta-3 inhibit retinal neovascularization in a murine model. Lab Investig 75:563-573.
20. Nambu H, Nambu R, Melia M, and Campochiaro PA (2003) Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Investig Ophthalmol Vis Sci 44:3650-3655.
21. Nilsson F, Kosmehl H, Zardi L, and Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:711-716.
22. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, and Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (Lond) 429:629-635.
23. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, and Campochiaro PA (1997) Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281-291.
24. Ozaki H, Seo M-S, Ozaki K, Yamada H, Yamada E, Hofmann F, Wood J, and Campochiaro PA (2000) Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156:679-707.
25. Pasqualini R, Koivunen E, and Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15:542-546.
26. Pasqualini R and Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature (Lond) 380:364-366.
27. Plate KH, Breier G, Millauar B, Ullrich A, and Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822-5827.
28. Plate KH, Breier G, Welch HA, and Risau W (1992) Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature (Lond) 359:845-848.
29. Ramakrishnan S, Olson TA, Bautch VL, and Mohanraj D (1996) Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56:1324-1330.
30. Ran S, Gao B, Duffy S, Watkins L, Rote N, and Thorpe PE (1998) Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58:4646-4653.
31. R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241-248.
32. Schnitzer JE (1998) Vascular targeting as a strategy for cancer therapy. N Engl J Med 339:472-474.
33. Seo M-S, Kwak N, Ozaki H, Yamada H, Okamoto N, Fabbro D, Hofmann F, Wood JM, and Campochiaro PA (1999) Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154:1743-1753.
34. Shweiki D, Itin A, Soffer D, and Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond) 359:843-845.
35. Smith LEH, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, and D'Amore PA (1994) Oxygen-induced retinopathy in the mouse. Investig Ophthalmol Vis Sci 35:101-111.
36. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427.
37. Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ, and Campochiaro PA (1998a) Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Investig Ophthalmol Vis Sci 39:180-188.
38. Tobe T, Ortega S, Luna L, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, and Campochiaro PA (1998b) Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153:1641-1646.
39. 121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99:7866-7871.
40. Verbeke G and Molenberghs G (2000) Linear Mixed Models for Longitudinal Data, Springer-Verlag New York Inc., New York.
41. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, and Baralle FE (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO (Eur Mol Biol Organ) J 6:2337-2342.